NCT07783711Not yet recruiting
Predictors of ICU Admission and In-Hospital Mortality in Hospitalized Patients With Lupus Nephritis: The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and C Reactive Protein to Serum Albumin Ratio
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
To identify clinical and laboratory predictors of ICU admission and in-hospital mortality among hospitalized adults with lupus nephritis by evaluating the prognostic performance of NLR and CAR, comparing them with CRP and albumin using ROC analysis, determining optimal cutoff values, and identifying independent predictors through multivariable logistic regression
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 55 (estimated)
- First submitted
- 21 Aug 2026
- Start date
- Sept 2026
- Primary completion date
- 1 Sept 2028
- Lead sponsor
- Khaled Samir Malak Nashed
- Diseases
- Lupus (SLE)
- NCT number
- NCT07783711
What you commit to
- Study type: Observational
- Planned participants: 55
- From Sept 2026 to the primary completion date, 1 Sept 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Age below 18 years.
- Previous kidney transplantation.
- Maintenance dialysis for more than three months before hospital admission.
- Active malignancy.
- Pregnancy.
- Refusal to participate
Who the study is looking for
- Age ≥18 years.
- Diagnosis of systemic lupus erythematosus according to the 2019 EULAR/ACR Classification Criteria.
- Biopsy-proven lupus nephritis or clinically diagnosed lupus nephritis according to the treating nephrologist based on clinical, laboratory and immunological findings.
- Hospitalization because of active lupus nephritis or complications related to lupus nephritis.
- Provision of written informed consent.
Age in the registry: 18 years to 70 years · Sex: All
This page is information, not medical advice. Discuss any trial with your doctor.